Skip to main content
. 2019 Sep 6;9:12840. doi: 10.1038/s41598-019-49150-9

Figure 2.

Figure 2

125I-Ad5A20 accumulates in Panc04.03 and Suit-2 pancreatic tumour xenografts after tail vein injection and imaged by SPECT/CT. (A) One animal with small bilateral subcutaneous and internal Panc04.03 tumours imaged by SPECT/CT. The αvβ6-retargeted, and radioactively labelled 125I-Ad5A20 mutant (8.2 × 109 vp/animal; 10.8 MBq/animal) was injected via the tail vein and imaged after 30 min, 2 h and 4 h. White solid arrows indicate subcutaneous tumour; white dashed arrows indicate internal tumour, one representative animal shown, n = 3. (B) Left panel; T2-weighted MRI image of one representative animal with a subcutaneous Suit-2 tumour in one flank indicated by white arrow, prior to virus administration. Right panel; Intravenous administration of the αvβ6-retargeted and radioactively labelled 125I-Ad5A20 in 200 µl (7 × 109 vp of 2.5 mBq/vp) in the same animal, imaged by SPECT/CT 24 h later. White arrows indicate tumour; white open arrow indicate bladder, one representative animal shown, n = 3. (A,B) The scale for all SPECT/CT images is 0.006–0.0225 kBq.